Effects of Curcuma extract and visible light on adults with XXXX .

@entity1 @entity6987 @entity1569 @entity6108
INTRODUCTION: We conducted a phase IV randomized, double-blind, placebo-controlled, pilot clinical trial to investigate the safety and efficacy of oral @entity6108 together with local phototherapy in @entity1 with @entity1569 . MATERIALS AND METHODS: @entity1 with moderate to severe @entity1569 received Curcuma extract orally with real visible light phototherapy (VLRT) or simulated visible light phototherapy (VLST) in the experimental area, while the rest of the body surface was treated with ultraviolet A (UVA) radiation. The endpoints were the number of responders and the temporal course of the response. The secondary outcomes were related to safety and adverse events. RESULTS: Twenty-one @entity1 were included in the study. In the intention-to-treat analysis, no @entity1 included in the VLRT group showed "moderate" or "severe" plaques after the treatment, in contrast to the @entity1 included in the VSLT group (p<0.01). Parallelisms in the evolution of @entity6987 , BSA, and PASI scores were observed in the two groups following the treatment. At the end of the study period, 76% of all @entity1 showed a response in the BSA exposed to UVA. Lesions on the experimental area showed a response in 81% of the @entity1 in the VLRT group and 30% of the @entity1 in the VLST group. There were no study-related adverse events that necessitated @entity1 withdrawal. CONCLUSION: The results suggested that moderate to severe @entity1569 should  show a therapeutic response to orally administered Curcuma if activated with visible light phototherapy, a new therapeutic method that would be safer for @entity1 than existing treatments.
